Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been given a consensus rating of "Hold" by the ten research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

A number of brokerages have weighed in on FULC. Royal Bank of Canada downgraded shares of Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their target price for the company from $15.00 to $4.00 in a research note on Thursday, September 12th. Leerink Partners reiterated a "market perform" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a report on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $10.00 to $2.00 in a report on Thursday, September 12th. Finally, HC Wainwright cut shares of Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $17.00 to $4.00 in a research note on Friday, September 13th.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently bought and sold shares of FULC. China Universal Asset Management Co. Ltd. grew its stake in shares of Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock worth $43,000 after acquiring an additional 4,701 shares during the period. SG Americas Securities LLC grew its position in Fulcrum Therapeutics by 26.5% in the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company's stock worth $118,000 after purchasing an additional 6,926 shares during the period. Algert Global LLC raised its stake in Fulcrum Therapeutics by 202.1% during the 2nd quarter. Algert Global LLC now owns 41,303 shares of the company's stock valued at $256,000 after buying an additional 27,633 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at $152,000. Finally, Caxton Associates LP purchased a new position in shares of Fulcrum Therapeutics in the 2nd quarter worth $117,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Down 1.5 %

Shares of NASDAQ:FULC traded down $0.05 during trading on Friday, hitting $3.19. The stock had a trading volume of 510,622 shares, compared to its average volume of 1,164,523. Fulcrum Therapeutics has a 12 month low of $2.87 and a 12 month high of $13.70. The firm's fifty day moving average is $5.41 and its 200 day moving average is $6.90.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.93. The business had revenue of $80.00 million for the quarter, compared to the consensus estimate of $80.00 million. During the same quarter last year, the firm posted ($0.38) EPS. As a group, equities research analysts anticipate that Fulcrum Therapeutics will post -0.28 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.